Positron emission tomography (PET) and the high affinity D 2/3 radiotracer [
INTRODUCTION
Neuroreceptor imaging has been widely used in the last two decades to assess D 2 receptor occupancy achieved by antipsychotic drugs (Kapur et al, 1999; Nyberg et al, 1998) and has contributed some fundamental observations to our understanding of the mechanisms underlying their effects. These studies have established the threshold of occupancy of striatal D 2 receptors (about 80%) above which extrapyramidal side effects (EPS) are likely to occur (Farde et al, 1992) and have suggested that 50-60% occupancy was required to observe a rapid clinical response (Kapur et al, 2000; Nordstrom et al, 1993) .
More recently, the development of high affinity D 2/3 radiotracers allowed assessment of occupancy by antipsychotics in extrastriatal areas where receptors are present in lower density. Pilowsky et al (1997) initially reported lower occupancy of striatal D 2 receptors compared to temporal cortex D 2 receptors with clozapine, using the high affinity SPECT ligand [
123 I]epidepride. In contrast, typical antipsychotics were reported to achieve similar occupancy in striatal and extrastriatal areas, as measured with [
11 C]FLB 457 (Farde et al, 1997) or [
123 I]epidepride (Bigliani et al, 1999) . Occupancy studies performed with [
76 Br]FLB 457 reported higher occupancies in cortex compared to striatum for a number of antipsychotic drugs, including typical antipsychotics (Xiberas et al, 2001) . However, these very high affinity ligands do not allow accurate determination of D 2 receptor availability in the striatum due to lack of equilibrium within the timeframe of the experiment (Talvik et al, 2001) . Conversely, [
18 F]fallypride enables accurate determination of D 2 receptor availability in both striatal and extrastriatal areas (Kessler et al, 2000) . Occupancy studies using [ 18 F]fallypride reported that clozapine and quetiapine, but not olanzapine or haloperidol, achieved higher D 2 receptor occupancy in temporal compared to striatal regions (Grunder et al, 2006; Kessler et al, 2005 Kessler et al, , 2006 . Thus, there is evidence that many antipsychotics achieve higher occupancies in temporal cortex than striatum, although this phenomenon has not been universally observed. Factors underlying this difference remain to be elucidated. Furthermore, D 2 receptor occupancy levels in striatum were observed to be more predictive of therapeutic response than in temporal cortex (Agid et al, 2007) . Thus, the observation that, in a restricted dose range, D 2 receptor occupancy by antipsychotic drugs is higher in temporal cortex than in striatum does not necessarily imply that the temporal cortex is the therapeutic site of action of these agents. In addition, the most robust preclinical evidence regarding the site of therapeutic effect of antipsychotic drugs points toward the ventral striatum (Deutch, 1992; Robertson et al, 1994) , while the imaging studies reviewed above contrasted striatal versus mesotemporal D 2 receptor binding.
Aripiprazole is a new antipsychotic used for treatment of schizophrenia with a distinct pharmacological profile due to its partial D 2 agonism (Kessler, 2007) . Two recent studies have assessed the occupancy of striatal D 2 receptors by various doses of the drug after at least 2 weeks administration, one in healthy subjects (Yokoi et al, 2002) and the other in patients with schizophrenia . The radioligand used for D 2 receptor assessment in those studies was [ 11 C]raclopride, which cannot provide quantitative information about D 2 receptor binding outside the striatum. Yokoi et al (2002) reported striatal occupancy levels ranging from 60 to 95% without notable EPS, contrasting with the usual presence of EPS at occupancy levels exceeding 80% for D 2 antagonists (Farde et al, 1992; Farde et al, 1988) . Similarly, Mamo et al (2007) found striatal occupancy levels ranging from 85 to 93% with minimal occurrence of EPS only at the highest occupancy levels. Another characteristic of this drug is the absence of prolactin elevation seen commonly with antipsychotic treatment, consistent with partial agonism of aripiprazole at pituitary D 2 receptors. Indeed, a recent study has found adjunctive treatment with aripiprazole to be efficacious in antipsychotic-induced hyperprolactinemia (Shim et al, 2007) .
It is unclear to what extent aripiprazole, at therapeutic doses, occupies extrastriatal D 2 receptors and the role this occupancy may play in the therapeutic effect. We used [ 18 F]fallypride to measure striatal and extrastriatal D 2 receptor occupancy as well as the effect on pituitary binding attained across a range of clinically determined dosing with aripiprazole in patients with schizophrenia. We also investigated the relationship between therapeutic response measured with the PANSS (Kay et al, 1987) and regional occupancy measurements to assess the likely site of antipsychotic effect.
METHODS

Subjects
The study was approved by the Institutional Review Boards of the New York State Psychiatric Institute (NYSPI) and Columbia University. Patients were recruited from the Schizophrenia Research Unit, NYSPI or the affiliated outpatient research clinic and provided written informed consent. Capacity to provide informed consent was evaluated by a psychiatrist not associated with the study. Patients were medically healthy and met inclusion criteria for schizophrenia or schizoaffective disorder, but no other DSM-IV (2000) Axis I diagnosis and no substance abuse by history confirmed with negative urine drug screens, and were free of any psychotropic medication for at least 21 days before the baseline scans and any psychotropic medication other than aripiprazole for at least 21 days before the occupancy scans (with the exception of lorazepam, which was allowed at a maximal dose of 3 mg/ day up to 24 h before the study). There were no occurrences of relapse during the medication-free period.
Nineteen patients (see Table 1 for clinical and demographic characteristics) underwent a total of 28 [ 18 F]fallypride scans. Patients' participation in baseline and occupancy scans is shown schematically in Table 2 . Nine patients (group A; Table 2 ) underwent two scans, one in the unmedicated condition (''baseline'' scan) and one on the study medication aripiprazole (''occupancy'' scan); two underwent only the baseline scan (group B, Table 2 ); and eight underwent only the occupancy scan (group C, Table 2 ). Thus, the 28 [
18 F]fallypride scans of the study consisted of 11 baseline scans and 17 occupancy scans. Pooled medication-free durations at baseline and treatment durations before occupancy scans are shown in Table 1 . For the baseline scans, four group A subjects were drug-naïve and the other 5 were off medications for 30-840 (234 ± 344) days, while the two group B subjects were off medications for 24 days and 7 years, respectively. At the time of occupancy scans, the duration of aripiprazole treatment for group A subjects was 10-49 (28 ± 13) days and for group B subjects was 10-140 (43±44) days. The daily clinically determined doses of aripiprazole were 2 mg (n ¼ 1), 2.5 mg (n ¼ 1), 5 mg (n ¼ 3), 7.5 mg (n ¼ 1), 10 mg (n ¼ 4), 15 mg (n ¼ 3), 25 mg (n ¼ 1), 30 mg (n ¼ 2), and 40 mg (n ¼ 1). Scans were obtained at a similar time of day (midafternoon).
Radiochemistry
[ 18 F]fallypride was prepared by reacting the starting material tosylate (2-3 mg) with resolubilized K[ 18 F]F/K222 in acetonitrile (1 ml) at 801C for 15 min. The starting material was prepared according to a modified literature procedure (Mukherjee et al, 1995) . The crude reaction mixture was mixed with water (20 ml) and passed through a C-18 Sep-Pak. The Sep-Pak was washed with 20 ml of 20% aqueous ethanol and the crude product was recovered with 1.5 ml of ethanol, which was then purified by a semipreparative HPLC method. The HPLC product fraction was mixed with 100 ml of water and passed through a C-18 SepPak. After 20% ethanol (10 ml) and water (10 ml) wash, the tracer was recovered from the Sep-Pak using 1 ml of absolute ethanol. The average radiochemical yield was about 30% at the end of bombardment or about 15% at the end of synthesis. A small sample from the ethanol solution was removed for the determination of specific activity, radiochemical purity, and chemical purity. The rest of the ethanol solution was diluted with saline (9 ml) and filtered through a sterile membrane filter into a vented sterile sample vial. The injected mass was 0.75±0.33 mg, specific activity was 1378±964 Ci/mmol, and activity dose was 2.39 ± 1.38 mCi at time of injection (n ¼ 28).
PET Scanning
Positron emission tomography (PET) imaging was performed in 3D mode with the high-resolution ECAT EXACT HR + scanner (Siemens/CTI, Knoxville, TN) (Brix et al, 1997) . Ten-minute transmission scans were obtained as detailed below. [ baseline scans, emission data were acquired over 240 min as 24 frames of increasing duration (3 Â 20 s, 3 Â 1 min, 3 Â 2 min, 2 Â 5 min, and 13 Â 10 min, totaling 150 min of acquisition time). During the 240 min, there were two breaks out of the camera as follows: at 50 min, a 10-min transmission scan was followed by a 20-min break and at 140 min, a 10-min transmission scan was followed by a 40-min break followed by a final 10-min transmission scan preceding the final acquisitions. Thus, emission data were obtained in three successive blocks of 50, 60, and 40 min. Occupancy scans, with their faster kinetics, were acquired over 120 min as 21 frames of increasing duration (3 Â 20 s, 3 Â 1 min, 3 Â 2 min, 2 Â 5 min, and 10 Â 10 min) in one uninterrupted block. The difference in scan duration between conditions was necessary because of the longer time to peak concentration of [ 18 F]fallypride in the baseline condition. Following aripiprazole treatment, calculated volumes of distribution were found to be time stable with 2 h of scanning in all brain regions (Laruelle et al, 2003) . PET emission data were attenuation-corrected using the transmission scans, and frames were reconstructed using a Shepp filter (cutoff 0.5 cycles/projection ray).
Input Function Measurement
Arterial access was available for n ¼ 25 of the 28 scans (all baseline scans and n ¼ 14 of the 17 occupancy scans). Following radiotracer injection, arterial samples were collected and radioactivity measured as described previously (Abi-Dargham et al, 1999) . Five plasma samples (collected at 2, 20, 40, 80, and 120 min) were processed by HPLC to measure the fraction of plasma radioactivity representing unmetabolized parent tracer. A three-exponential-fitted input curve for kinetic analyses was generated as described previously (Abi-Dargham et al, 1999) .
Clinical Ratings and Assessment
The PANSS rating scale (Kay et al, 1987) was administered twice, at baseline (while unmedicated) and on the study dose of aripiprazole, to seven of the nine patients who underwent both [
18 F]fallypride baseline and aripiprazole occupancy scans. The remaining subjects had ratings only at baseline (n ¼ 4) or on treatment (n ¼ 8), that is, two of the patients were not rated on medication. Clinical assessment of extrapyramidal signs and akathisia was made at the time of the occupancy scan by the treating psychiatrist for all the 17 subjects receiving aripiprazole.
Plasma Aripiprazole Levels
Plasma aripiprazole was assayed (Analytical Psychopharmacology Laboratory, Nathan Kline Institute, Orangeburg, NY) using reverse phase liquid chromatography with ultraviolet detection. Blood for these assays was drawn at the time of PET scan just before radioligand injection and at the end of scan 2 h later. The two plasma levels for each scan were averaged and compared with the daily dose of aripiprazole (Figure 1) , showing a high correlation (n ¼ 15, Pearson's R ¼ 0.814, p ¼ 0.0002). Given this high correlation, since plasma samples were unavailable for 2 of the 17 subjects participating in occupancy scans, subsequent analyses of occupancy were performed in comparison to aripiprazole dose rather than plasma levels.
PET Data Analysis
Each patient underwent a high-resolution T1-weighted magnetic resonance imaging (MRI) scan on a GE-Signa 3T system. For each PET scan, frame to frame registration (Woods et al, 1993) using the MEDx (Sensor Systems Inc., Sterling, VA) software environment was followed by coregistration to the subject's MRI using mutual information maximization as implemented in SPM2 (Friston et al, 1995) . The following regions of interest (ROIs) were drawn on each subject's MRI using MEDx: cerebellum; pituitary; 5 striatal subregions (precommissural dorsal caudate, posterior caudate, precommissural dorsal putamen, posterior putamen, ventral striatum (Martinez et al, 2003) ); and 7 extrastriatal regions (amygdala, thalamus, hippocampus, temporal cortex, insula, midbrain, and entorhinal cortex). Right and left regions were averaged. Outcome measures were calculated using two methods. The first of these was the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) , yielding BP ND (n ¼ 17), a binding potential measure denoting the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue (Innis et al, 2007) . The second method was the two tissue compartment model with arterial input function (2TCM), yielding both BP ND and BP P , the latter referring to the ratio at equilibrium of specifically bound radioligand to that of total parent radioligand in plasma (Innis et al, 2007) (n ¼ 14; three subjects lacked arterial access for the occupancy scan). For each of these three BP measures, occupancy by aripiprazole was computed in each region as 100% * (1ÀBPocc/BPbsl), where 'occ' refers to the scan while medicated and 'bsl' refers to each individual's own scan off aripiprazole for group A, or to the mean of the n ¼ 11 off-aripiprazole scans for group C. For comparison, occupancy was also calculated for subjects in group A using 'bsl' as the average of the 11 off-aripiprazole scans. The results of the two different 'bsl' methods are referred to in the Results section as 'mixed baseline' in the former case and 'average baseline' in the latter. A pituitary ROI dose-response estimate was made separately using a non-model-based approach. Tracer kinetics modeling relies on assumptions that may be unreliable for the pituitary, which is outside the bloodbrain barrier (BBB): (1) the BBB excludes any radiolabeled metabolites of the parent radioligand from penetrating the ROI and contaminating the signal and (2) a reference region free of D 2 receptors provides a reliable estimate of nondisplaceable binding in the modeled ROI. Therefore, a procedure for estimating the effect of aripiprazole on [ 18 F]fallypride signal in pituitary that avoids these assumptions was used. We computed the percent change in the area under the pituitary time-activity curve (AUC), normalized to injected dose of radioligand, between the baseline and occupancy scans, for the nine subjects in group A. The AUC was sensitive to the scan truncation time and was evaluated two ways, by (1) truncating at end of scan, which was at 120 min for occupancy scans and 240 min for baseline scans and (2) truncating all scans uniformly at 120 min. The AUC more closely corresponds to the total volume of distribution V T than to BP, and no estimate of nonspecific binding was made. For this reason, the measured fractional changes following aripiprazole in pituitary were expected to be less than the occupancy measures computed in brain ROIs. For comparison, SRTM using cerebellum as a reference region was applied to these data as well.
Statistical Tests
Group means are presented as average±SD.
Regression analysis with the Pearson's correlation coefficient was used to compare plasma aripiprazole levels to aripiprazole dose, as well as to compare D 2/3 receptor occupancy by aripiprazole to changes in PANSS subscale ratings.
ED 80 values for each of the ROIs were obtained by use of the Prism software system (GraphPad Software Inc., San Diego, CA) to fit the dose-occupancy data for each region assuming a range from 0 to 100% occupancy. Pooled data from all regions were used to test the hypothesis of a single ED 80 for all brain regions vs different ED 80 values in striatal subregions and extrastriatal regions (F-test). The choice of the ED 80 rather than the ED 50 was based on its greater relevance to the clinical range of medication dosing, but statistical tests are unchanged, since the ED 80 is a fixed multiple (four) times the ED 50 , affecting means and SDs equally.
RESULTS
Injected doses, masses, and specific activities of [ 18 F]fallypride did not differ between baseline and occupancy scans (Table 3) . There was no change in V ND (cerebellum V T ) on aripiprazole compared to baseline in the six subjects with arterial access during both scans ( ( Lahti et al, 1995; Rieck et al, 2004) . At baseline, extrastriatal uptake was about 5% of striatal uptake (see Figure 2 and left 'baseline' panel of Figure 3 , where the average baseline [ 18 F]fallypride BP ND computed on a voxelwise basis using the SRTM across the nine patients in group A is displayed in a common anatomic space). Similar results were obtained with 2TCM. The remaining panels in Figure 3 show the effects on [ 
Regional Receptor Occupancy
In general, for the wide range of clinically determined dosing of aripiprazole in this study, occupancy levels were high across both striatal and extrastriatal regions. Occupancy levels averaged over all subjects and all regions ranged from 71.6 ± 5.5% at 2 mg/day dose to 96.8 ± 5.3% at 40 mg/day based on 2TCM. However, the data showed a systematic difference between striatal and extrastriatal regions.
We generated dose-occupancy curves as described in the Methods section for each of the 12 regions analyzed, yielding the ED 80 for each region. All available cases (groups A and C) were included for each of the three outcome measures: BP ND using SRTM (n ¼ 17) and BP ND as well as BP P using 2TCM (n ¼ 14 with arterial access). These different outcome measures consistently showed higher occupancy in extrastriatal compared to striatal regions for a given dose. For example, striatal occupancies were 79.8±14.8% compared with 83.1±10.9% extrastriatal at 10 mg/day and 83.5 ± 3.2% striatal compared with 85.5 ± 9.0% extrastriatal at 15 mg/day based on SRTM. Equivalently, the ED 80 was higher in the striatum than in extrastriatal regions. As seen in Figure 4 , the mean ED 80 for 2TCM was 44% greater in the striatal compared with the extrastriatal regions, corresponding to higher mean extrastriatal occupancy. This difference, while corresponding to the clinically relatively small ED 80 dose difference of 1.7 mg/ day, is statistically significant (F-test, p ¼ 0.004). The results for all three outcome measures using 'mixed baseline' and 'average baseline' are shown in Table 4 , showing similar ED 80 differences with all outcome measures. Specific regional results for subjects in group A are displayed in Figure 5 .
Effects of Modeling Method
Occupancy computations based on all combinations of modeling method and subject grouping were in substantial agreement on the dose-occupancy relationships and the greater ED 80 values in striatum compared to extrastriatal regions (Table 4 ). There was a tendency for SRTM to yield systematically lower values of occupancy (higher ED 80 ) compared with 2TCM. This was also the case for baseline BP ND values as shown by region in Table 5 . 2TCM baseline BP ND values were 27±7% higher than the SRTM values, although the two methods were highly correlated (r ¼ 1.00, po0.0001). The 'average baseline' method yielded poorer statistical power to detect striatal/extrastriatal differences as expected by the sacrifice of specific knowledge of the within-subject baseline BP values for the nine cases where such data were available.
Clinical Ratings and Assessment
For the seven subjects who were rated with the PANSS scale before and after aripiprazole treatment, the relationships between the changes in the subscales and aripiprazole occupancy were evaluated. As shown in Figure 6 , the positive-symptom subscale changes correlated positively with striatal subregional occupancy. The extrastriatal regions examined individually showed no such correlations, and the negative-symptom subscale changes showed no significant correlation with occupancy in striatal or extrastriatal regions.
Pituitary
The estimation method for the pituitary showed a clear dose response, with fractional AUC decreases following aripiprazole ranging from 39.3±14.9% at 2 mg/day to 67.3±0.2% at 30 mg/day. This is consistent with the expectation that decreases in AUC would be relatively less than decreases in brain BP due to the lack of correction for nonspecific binding ( Figure 7A ). In addition, truncation of all integrations at 120 min further decreased the estimated change in pituitary AUC, ranging from 13.7 ± 5.1% at 2 mg/ day to 49.0±0.4% at 30 mg/day ( Figure 7B ). This can be understood by noting that the slower kinetics of the baseline scans results in greater contribution to the AUC after 120 min for baseline than for occupancy scans. SRTM modeling produced a nearly uniform decrease that was independent of dose (ED 80 ¼ 10.8 mg; Figure 7C ), suggesting that pituitary data were not well characterized by this model. Qualitatively, Figure 7 suggests that pituitary D 2 receptor occupancy by aripiprazole may be similar to the striatal and extrastriatal brain regions examined.
Prolactin levels were obtained on aripiprazole for n ¼ 8 of the subjects and in all cases were within the normal range for this hormone and unrelated to the extent of pituitary occupancy by aripiprazole.
DISCUSSION
These data show, for the first time, in patients with schizophrenia, simultaneous striatal and extrastriatal regional D 2 receptor occupancy by a wide range of clinically relevant doses of aripiprazole. Consistent with previous findings Yokoi et al, 2002) , we observed high D 2 receptor occupancy by aripiprazole in the absence of EPS or prolactin elevation. These results are consistent with aripiprazole's high affinity for the D 2 receptor and its Figure 5 Bar charts showing occupancy by aripiprazole computed with SRTM for nine subjects in striatal subregions (anp, anterior putamen or precommissural dorsal putamen; dca, precommissural dorsal caudate; pca, posterior caudate; pop, posterior putamen; vst, ventral striatum) (a) and extrastriatal regions (ins, insula; tha, thalamus; mid, midbrain; tem, temporal cortex; amy, amygdala; ent, entorhinal cortex; hip, hippocamus) (b) at 2, 5, 10, and 30 mg/day. Occupancy was above 50% at the lowest dose of 2 mg/day of aripiprazole, and reached 75-80% at 10 mg/day. For many regions, the 30 mg/ day dose resulted in occupancy in the 90% range.
behavior as a partial agonist for D 2 receptor-mediated inhibition of cAMP accumulation, with intrinsic activity B25% that of dopamine (Burris et al, 2002) . In this study, consistent with the expected effects of a partial agonist, increasing concentrations of aripiprazole blocked dopamine's action, with maximal blockade equal to the agonist effect of aripiprazole alone. In this scenario, aripiprazole would function as a D 2 receptor antagonist in the presence of high dopamine stimulation, but would maintain baseline D 2 receptor signaling above that of no agonist stimulation. The notion that a single compound acts at a given receptor to produce a similar effect in all effector pathways appears to be oversimplified, and there is increasing evidence that a ligand can have different intrinsic activities at different effectors and in different cellular contexts (Mailman, 2007; Urban et al, 2007a) . This mechanism has been termed 'functional selectivity' (Lawler et al, 1999) or 'agonist trafficking' (Kenakin, 1995) . Indeed, aripiprazole has been found to have a complex pharmacology consistent with functional selectivity at the D 2 receptor. Although in some cellular systems aripiprazole behaves as a partial agonist at cAMP accumulation, in other cellular contexts it behaves as a full antagonist (Shapiro et al, 2003) . Furthermore, aripiprazole behaves as a partial agonist at calcium mobilization (Jordan et al, 2007) , MAP kinase activation (Jordan et al, 2007; Urban et al, 2007b) , and promotion of arachidonic acid release (Urban et al, 2007b) . In addition, aripiprazole, unlike dopamine, did not lead to D 2 receptor internalization, also consistent with its functional selectivity (Urban et al, 2007b ). Aripiprazole's in vivo behavior as a presynaptic D 2 receptor agonist and postsynaptic D 2 receptor antagonist (Kikuchi et al, 1995) may result from the interplay of its functional selectivity in these different cellular contexts.
A property of G protein-coupled receptors proposed to help explain functional selectivity effects is that of constitutive activity. In the absence of ligand, receptors isomerize between different conformations, some inactive and some, by virtue of their capability to activate Gproteins, active (Samama et al, 1993) . A partial agonist may be a 'protean' agonist in that its effect may vary depending on the level of intrinsic activity of the system. In quiescent systems, the ligand would be an agonist, whereas in a sufficiently constitutively active system it would be an inverse agonist (Kenakin, 2007) . Thus, although the exact molecular mechanisms at play are under active study and not yet well understood, these studies support a unique pharmacology for aripiprazole and may provide the beginning of a molecular understanding of its ability to block some aspects of D 2 receptor signaling while preserving or even enhancing others. Our findings suggest that imaging can provide a powerful approach to explore functional selectivity in vivo and to differentiate the pharmacological properties of D 2 receptor ligands. 
Differential Occupancy
This is the first report of combined striatal and extrastriatal D 2 occupancy for aripiprazole, showing a slightly but significantly higher differential occupancy of extrastriatal vs striatal D 2 . This finding should be discussed in two ways: its clinical implications and its theoretical mechanistic underpinnings. Clinically, mean ED 80 regional differences of about 2 mg/day are probably too small to be meaningful for clinical treatment considering that this drug is usually used in doses of 10 mg/day and higher. Nevertheless, this may be relevant for the therapeutic effect that may be observed at the lower doses of 2 and 5 mg, which will result in predominantly more extrastriatal than striatal occupancy. It may be interesting to better characterize patients who respond at this lower level in terms of their baseline pathophysiology, assessing factors such as dysregulation of baseline dopamine in extrastriatal regions and whether these predict the therapeutic response. No such evidence is available at this point, but this investigation is now possible with the use of tracers that assess extrastriatal D 2 receptors, such as [ Mechanistically, there could be multiple explanations for this observed difference. One is a difference in regional occupancy of receptors by endogenous dopamine, either due to different dopamine levels or different average regional affinities of D 2 receptors for dopamine. If the differences in regional ED 80 values arise solely from binding competition between aripiprazole and endogenous dopamine, a linear relationship between the ratios of dopamine to its inhibition constant (denoted R DA , see Appendix) in extrastriatal vs striatal brain regions can be inferred. The differences in ED 80 of Figure 4 give an estimate of the greater endogenous dopamine occupancy of striatal D 2 receptors compared with extrastriatal regions. For example, striatal endogenous dopamine occupancy of 31% (R DA ¼ 0.44 in striatum) corresponds to negligible extrastriatal occupancy of 0% (R DA ¼ 0, extrastriatal). However, using a-MPT depletion of DA, we have previously measured baseline occupancy of D 2 receptors by dopamine at levels close to 20% in patients with schizophrenia (Abi-Dargham et al, 2000) . At this level, the linear model would predict negative occupancy in extrastriatal regions (Figure 8 ), suggesting that competition with dopamine is at best only a partial explanation of the observed difference in regional aripiprazole occupancy.
Another possible mechanism is a higher affinity of the D 2 receptor for aripiprazole in extrastriatal regions vs striatal regions so that the same dose results in a higher binding in extrastriatal regions vs striatal regions. A higher affinity in turn could result from differences in the receptor or differences in the proportion of receptors in the high affinity (D 2H ) vs low affinity (D 2L ) state for dopamine. These differences could be related to differences in baseline dopamine levels. It is known that dopamine in the striatum Figure 7 Estimated pituitary occupancy by aripiprazole computed by integrating AUC using full scan acquisition times (a), truncating all integration times to 120 min (b) and using SRTM analysis with cerebellum as reference region (c) showing results for 2, 5, 10, and 30 mg/day in the n ¼ 9 subjects with baseline and occupancy scans.
PET aripiprazole occupancy study in schizophrenia LS Kegeles et al ranges from nM to mM levels, while in the cortex it ranges from pM to nM levels (Seamans and Yang, 2004) , with the overall tissue content of dopamine in the prefrontal cortex about 100-fold less than that in the striatum (Garris et al, 1993) . Higher dopamine could result in lower D 2H and lower binding of a partial agonist, such as aripiprazole, thus lower occupancy. This explanation is somewhat speculative, however, as the intrinsic activity of aripiprazole is quite low and differences in its affinity for D 2H and D 2L are quite small in vitro (Urban et al, 2007b) .
A mechanism that would cause an artifact leading to apparent occupancy differences is regionally different reregulation (ie, upregulation) of receptors in response to aripiprazole treatment. If, for example, there were upregulation of receptors in striatum only, then apparent striatal occupancy would be artifactually diminished, due to increased BP of [ 18 F]fallypride during the occupancy scan associated with an increased receptor pool and not directly attributable to regionally different aripiprazole occupancy. Our methods would be unable to discriminate between such an artifact and authentic regional occupancy differences.
Another source of possible artifact in the measured occupancy differential across regions is related to the kinetic interaction between aripiprazole and [
18 F]fallypride. The model we have used to estimate occupancy is based on the assumption that aripiprazole concentration is constant during the scanning period, but in fact it is changing, moving from peak to trough values over the course of the dosing cycle. While the terminal plasma washout half-life of steady state aripiprazole concentration has been estimated to be in excess of 60 h (Mallikaarjun et al, 2004) , the measured peak to trough change is more rapid. For example, Figure 2 in Mallikaarjun et al (2004) shows measured plasma concentration changes of up to 30% over 8-9 h, corresponding to an half-life in the range of 15-16 h.
If receptor occupancy by aripiprazole is changing at a similar rate during the scanning period, our method would measure a weighted average of the dynamically changing receptor occupancy. The weights would depend on the interaction between bound aripiprazole and unbound [ 18 F]fallypride, and unbound [
18 F]fallypride concentration in turn varies across regions as a function of receptor density. The model and simulations we present in the Appendix suggest that this phenomenon could account for regional differences in occupancy estimates if scanning was consistently performed during the peak to trough phase of the dosing cycle, with bound aripiprazole changing at a similar rate as the plasma changes in Mallikaarjun et al (2004) , but we have no evidence for the amount of aripiprazole change and scanning was performed at least 6 h after the last dose.
Another potential source of artifactual regional occupancy differences might be the presence of D 2/3 receptors in the cerebellar region of reference, assumed to be devoid of these receptors. The presence of a small number of receptors in the reference region might be expected to affect lower D 2/3 density ROIs more than higher density ROIs, producing a regional bias artifactually. As noted, however, we found no change in V ND (cerebellum V T ) due to the presence of aripiprazole compared to the baseline in the six subjects with arterial access during both scans, indicating the absence of this potential confound. Furthermore, as shown in the Appendix, the presence of receptors in the reference region would in fact bias all regions in the same way, regardless of ROI receptor density, again eliminating cerebellar D 2/3 receptors as a potential confound.
The radiotracer we used does not distinguish between D 2 and D 3 receptors. It is known that the D 3 is present in discrete regions of the brain such as the ventral striatum, globus pallidum, and thalamus. Occupancy in these regions reflects both receptor populations.
Clinical Ratings
Correlations of ratings of clinical improvement of positive symptoms with occupancy in striatal regions should be regarded as preliminary, since the number of subjects rated was small (n ¼ 7) and the relationship was significant in ventral striatum but only trend level in associative striatum. Furthermore, noisier occupancy data in extrastriatal regions arising from markedly lower D 2/3 receptor density may have masked associations in these regions. However, these correlations are in agreement with one previous finding (Agid et al, 2007) and suggest that this partial agonist agent, as do D 2 antagonists, benefits positive symptoms of schizophrenia through its modulation of striatal but not cortical or other extrastriatal dopamine activity. These data are consistent with the predominant involvement of limbic and associative striatum compared to sensorimotor striatum in the therapeutic effect of antipsychotics. Treatment was optimized for each patient independently of the study and the scan was obtained shortly after initiation of treatment except for four patients treated for 6 weeks or longer (for the remaining patients, treatment duration was 10-37 days, mean 23 ± 9 days). It has been reported that most of the therapeutic response is measured in the first 4 Figure 8 Plot of R DA,E (the ratio of extrastriatal free dopamine concentration to the dopamine-D 2 receptor dissociation constant) vs R DA,S (same ratio for striatal dopamine) for a range of R DA,S values (see Appendix) using the ED 80 ratio value .693 obtained with the BP ND outcome measure evaluated using kinetic modeling (Figure 4 ). This graph shows that this ED 80 ratio is compatible with dopamine R DA,S greater than .44 (the intercept on the x-axis), or striatal occupancy greater than 31%.
weeks of treatment (Kerwin et al, 2007) , so we predict that the treatment response measured here is likely to be close to the optimal response. The lack of relationship with improvement in negative symptoms suggests that treatment of negative symptoms is more multifactorial than that of positive symptoms and may depend on occupancy of other systems and in other regions.
Four cases were studied after a more prolonged treatment as noted. In these four cases, occupancy measures can be underestimated due to increases in receptor expression with chronic treatment. These changes are likely to be minimal in the first few weeks, and are likely to be minimal with a partial agonist (Inoue et al, 1998; Ozdemir et al, 2002) .
Pituitary Gland
Aripiprazole appears to occupy a significant proportion of D 2 receptors in the pituitary, with no correlation between occupancy and prolactin levels. These estimates are the first ever derived from in vivo imaging data; to our knowledge, no quantification of D 2 -like receptor occupancy in the pituitary has been published, although D 2 radioligand binding in this region has been demonstrated qualitatively (Bergstrom et al, 1991) . Measuring occupancy in the pituitary is a challenge due to the absence of applicable models. However, within these constraints, we used a straightforward method based on the AUC. As a result, the denominator in the expression for the percent changes includes nonspecific binding and possibly radiolabeled metabolites. These quantities were not expected to change across conditions, so that the observed systematically lower change compared to the occupancy condition as measured in brain was not a surprise. For the sake of comparison, we also computed the conventional occupancy measure in pituitary, using SRTM with cerebellum as reference region. While substantial apparent occupancy was observed with this approach, the results were not well correlated with dose ( Figure 7c ). Although it remains for future work to characterize the pharmacokinetics of this structure more precisely, the substantial pituitary occupancy observed in the absence of prolactin elevation argues for sufficient partial agonism of aripiprazole at pituitary D 2 receptors to avoid the functional antagonism that leads to prolactin elevation with other antipsychotic medications.
Substantia Nigra
The substantia nigra has previously been reported to be relatively spared of D 2 occupancy by atypical antipsychotic medications such as clozapine and quetiapine compared with cortical regions (Kessler et al, 2006) . On inspection, we found that our midbrain ROI definition closely encompassed the substantia nigra as defined in Kessler et al (2006) , and our data show no such occupancy sparing for aripiprazole in that region, with over 65% occupancy at 2 mg/day and over 90% occupancy at 30 mg/day, based on SRTM, comparable to other extrastriatal regions.
CONCLUSION
In conclusion, this study is the first report on extrastriatal and striatal D 2 receptor occupancy in patients with schizophrenia by various doses of aripiprazole, a partial D 2 receptor agonist, and the first estimate of pituitary D 2 receptor occupancy. We confirm the in vivo partial agonism of the drug as we find high occupancies in the absence of EPS or prolactin elevations. In addition, we find higher occupancy by aripiprazole in extrastriatal compared with striatal regions, although the differential occupancy is small and the clinical improvement in positive symptoms is related to striatal rather than extrastriatal regions. Higher extrastriatal occupancy by aripiprazole may be related to higher striatal than extrastriatal dopamine concentrations but also could be an artifact derived from differential kinetics across these regions. Further studies using established methods of assessing dopamine function such as amphetamine-induced dopamine release or dopamine depletion for evaluating baseline dopamine levels are needed to investigate this finding. These studies may also clarify the issue of potential therapeutic effect of extrastriatal occupancy by providing information about baseline stimulation of the D 2 receptors in these regions.
A.1: Derivation of dopamine occupancy ratios from regional differences in ED 80 The assumptions in this estimating procedure are that (i) aripiprazole has the same affinity for all D 2 -like receptors in all regions, (ii) the concentration of dopamine in the proximity of the receptors is not substantially changed following aripiprazole treatment compared to baseline, and (iii) ED 80 ratios between regions are equivalent to EC 80 ratios between regions.
Let R A,S , R A,E , R DA,S , and R DA,E be the ratio of concentration to inhibition constant for aripiprazole (A) and dopamine (DA) in striatum (S) and extrastriatal regions (E). Then, occupancy in both region types is equal to
Let Figure 8 is a plot of R DA,E vs R DA,S for a range of R DA,S values using the ED 80 ratio value of .693 observed in this data set generated from BP ND values from 2TCM (Figure 4) .
A.2: Drug occupancy measured by PET when drug concentration is changing during the scan
Theory
An underlying assumption used to derive aripiprazole occupancy from the fractional change in BP is that the bound drug concentration is constant during the scanning period. If this quantity is changing during the course of the scan, the apparent occupancy will then be a weighted sum of the dynamically changing occupancy over the course of the scan, and the weights will be influenced by timevarying free concentration of the radioligand. Free radioligand concentration will be different across brain regions, due to the ability of the receptor pool to act like a capacitance, removing ligand from the free compartment by specific binding in the early scan phase when free ligand exceeds the equilibrium binding point, and returning ligand to the free compartment in the later phase when specifically bound ligand exceeds the equilibrium point. The phenomenon will be more pronounced in high receptor density regions (striatum) than in low receptor density regions (cortex and limbic regions), leading to different weights in the estimated occupancies. In particular, if receptor-bound drug was in an approximately exponentially decreasing phase during the course of the scan, the following analysis and simulation show that this phenomenon could cause apparent differences in occupancy in the absence of true differences.
In addition to the standard modeling assumptions regarding rapid equilibration of radioligand free fractions and constant V ND (nonspecific distribution volume) across regions, we also assume here that arterial plasma clearance of the radioligand is the same across conditions. This is only for computational simplification, and does not materially affect the result.
In this study, occupancy is measured as
where drug and baseline refer to the scan conditions. Based on the assumptions above and the fact that compartmental distribution volumes are equivalent to the ratio of the AUC to infinity of the compartment to the AUC of the arterial plasma, and denoting the specifically bound compartment C S , the right-hand side of this expression simplifies to
AUCðC S with drugÞ AUCðC S at baselineÞ Â100% This is an identity when the modeling assumptions are met exactly. If receptor availability is changing over the course of the scan during the drug condition, the equation is an approximation in the sense that the fitting procedure will find the closest curve to the data from the set of all curves that fit the model equations by least squares minimization, and AUC(C S ) of this curve will be influenced by, although not necessarily identical to, AUC(C S ) of the data. The AUCs can be derived from the linearized mass action laws for the conditions. Denoting the nondisplaceable compartment as C ND ,
The parameter k 3 equals the constant f ND k on B max during the baseline condition. Its explicit time dependence applies during the drug occupancy condition. The effect of the drug is represented as a multiplicative factor (k 3 (t)) due to tracer conditions for the radioligand, so that the drug concentration is not perturbed by the presence of the tracer, and tracer 'sees' a time-varying receptor availability. The solution to this differential equation is For the case that the bound drug is decreasing exponentially, DðtÞ % 1-occ 0 e Àlt where occ 0 is the occupancy at the beginning of the scan and the rate constant is l ¼ ln(2)/t where t is the half-life of the drug washout from the receptors. Substituting for D and simplifying leads to DBP ND ¼ occ 0 AUC e Àlt C ND ðdrugÞ À Á AUC C ND ðbaselineÞ ð Þ Finally, noting AUC(C ND (baseline)) is equal across regions, it can be seen that it is possible for occ 0 to be the same across regions, but still have regional differences in estimated occupancy due to differences in AUC(eÀltC ND (drug)). Apparent occupancy will therefore be affected by three factors: occ 0 and the regional difference in B max , each of which influences the shape of C ND during the drug condition, and t, the half-life of the drug.
Simulations To test the predictive power of this analysis, simulations were performed. Time activity curves were generated using a plasma input function and kinetic parameters similar to human [ Simulation results ¼ mean±SD over n ¼ 1000 trials at each initial occupancy and half-life combination. Mallikaarjun et al (2004) (also see discussion section), drug off-rates were tested in the range of 10-20 h. For each initial occupancy and washout rate combination, 1000 pairs of curves were generated in each region with Gaussian noise according to the formula C(t) Â (1 + 0.05z), where z was sampled from a standard normal distribution and C(t) was the noise-free time activity curve. Data were then fitted and occupancy computed according to the methods used in the study. Results (Table A1) show that both for the AUC-based prediction and the simulations, striatum occupancy was slightly but consistently less than hippocampus. The results also show that the AUC analysis is numerically closer to striatum fits than hippocampus; in hippocampus, the estimated occupancies are closer to the initial values than the AUC equation predicts. The differences are greatest at high (90%) initial occupancy, where the simulated regional differences are comparable to those seen in the aripiprazole study.
A.3: Effect of D 2/3 receptors in the reference region
This section of the Appendix shows that the presence of D 2/3 receptors in the reference region would not differentially 
so that there is a bias (true occupancy ¼ 1Àa) but it affects all regions to the same extent.
